Lilly’s latest China drug deal; Immunovant’s setback in lupus

AI Summary

Lilly has committed up to $3.35 billion in a new drug alliance focused on the Chinese market, marking its fourth partnership in China since January 2025. Additionally, an RNA drug showed success against a rare form of ALS, boosting confidence in Vertex's prospects.

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.